Indivior Announces FY 2019 Financial Results
FY 2019 Adjusted
Financial Results In-Line with Guidance. FY 2020 Guidance Introduced.
| Period to Dec. 31st | Q4 2019 $m | Q4 2018 $m | % ∆ Actual FX | % ∆ Constant FX | FY 2019 $m | FY 2018 $m | % ∆ Actual FX | % ∆ Constant FX |
|---|---|---|---|---|---|---|---|---|
| Net Revenue | 133 | 236 | -44 | -43 | 785 | 1,005 | -22 | -21 |
| Op. (Loss)/Profit | (42) | 20 | NM | NM | 178 | 292 | -39 | -36 |
| Net (Loss)/ Income | (55) | 24 | NM | NM | 134 | 275 | -51 | -47 |
| EPS (cents/share) | (8) | 3 | NM | NM | 18 | 38 | -53 | -46 |
| Adj. Op (Loss)/Profit* | (46) | 78 | NM | NM | 202 | 332 | -39 | -36 |
| Adj. Net (Loss)/ Income * | (37) | 67 | NM | NM | 176 | 272 | -35 | -31 |
| Adj. Basic EPS* | (5) | 9 | NM | NM | 24 | 37 | -35 | -31 |
* Adjusted basis excludes the impact of exceptional items as referenced in Notes 3 and 4 on pages 20 and 21. NM: not meaningful
This Release Contains Inside Information.
Comment by Shaun Thaxter, CEO of Indivior PLC
“2019 was a challenging year for Indivior but I am proud that it brought out the very best in our people as we focused our efforts on improving the lives of patients suffering from addiction and its co-occurring disorders. Our solid operating performance allowed us to raise our full-year financial guidance twice, helped by the resilience of SUBOXONE® (buprenorphine and naloxone) Film in the face of buprenorphine/naloxone film generics and by our strict financial disclipline and cash conservation. At the same time, we were able to lay the foundations for the future success of our key growth drivers, SUBLOCADE® (buprenorphine extended-release) injection and PERSERIS® (risperidone) extended-release injection, while also further extending our scientific leadership in opioid use disorder (OUD).
Looking to 2020, I am inspired by the opportunity we have in front of us to profoundly impact patient lives in a more meaningful way: our groundbreaking direct-to-consumer (DTC) campaign is focused on helping more patients connect to treatment and our publication of new science is building a strong evidence base supporting SUBLOCADE®’s differentiated product profile. Supported by our enhanced compliance capabilities to meet the growing number of buprenorphine medication-assisted treatment (BMAT) patients and prescribers, we expect these efforts to help us make marked progress toward our peak net revenue goal of $1bn for SUBLOCADE®. With our new schizophrenia depot PERSERIS® also set to deliver a greater net revenue contribution, 2020 is shaping up to be a pivotal year for Indivior.
Although we are optimistic about delivering on our strategic priorities in 2020, we of course recognise the legal uncertainties we face. We are proactively working to manage these risks while our teams remain focused on leveraging the strategic and operational accomplishments of the past year to further our leadership position in addiction science and diversification into behavioral health.
Read the full report here.